article thumbnail

11 investors predict a colorful, if difficult, future for psychedelic startups

TechCrunch

Amongst these questions are actual costs of therapies, reimbursement coverage, the commercialisation strategy for psychedelic drug development companies, resource bottlenecks with the therapists’ supply and infrastructure, etc,” they told TechCrunch+.

startup 99